Vault PromoMats

Electronic Certificate	
Document Number:	SA-UPAD-210010
Document Name:	* Upadacitinib aRM Tool - Patient Alert Card - English Version 2.0 - June 2021

Certification Statement

I hereby certify that I have examined the material referred to above and confirm that:

1. The piece has been approved according to the relevant Code, SOPs and Regulations

2. The information in the piece is balanced, accurate and a truthful presentation of the facts

3. When applicable, the content is consistent with the local Health Authority labeling document(s)

4. If applicable, the electronic version of the attached artwork is suitable for release to the market

Role	Signature
Medical Certification	Yasser Nour Medical Director 17-Nov-2021 11:10:08 GMT+0000

Show this card to any healthcare professional involved in your medical care – for example, your dentist or an emergency doctor.

▼ This medicinal product is subject to additional monitoring. You can help by contacting the below mentioned address to report any side effects.

• For Extra copies please contact AbbVie Biopharmaceuticals GmbH 00966 55 828 2010

To report any side effects for Rinvoq please contact AbbVie Biopharmaceuticals GmbH - Hot Line: 00966 55 828 2010
Mailbox: MEAPV@abbvie.com

National Pharamacovigilance Center Saudi Food and Drug Authority - Fax: +966 11 205 7662 - SFDA Unified Call Center: 19999
E-mail: npc.drug@sfda.gov.sa | Website: https://ade.sfda.gov.sa/

Your name:

.....

Consultant's name – who prescribed RINVOQ®:

.....

Consultant's phone number:

.....

The date you started RINVOQ®:

.....

Version 2.0. Date approved June, 2021.
https://ade.sfda.gov.sa/

abbvie

Patient Alert Card

Keep this card with you all the time

This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

Safety Information about RINVOQ® ▼ (upadacitinib) for patients

- This card contains important safety information you should be aware of – before and during treatment with RINVOQ®.
- Read the patient information leaflet for more information.

Risk of infections

RINVOQ® may make an existing infection worse or increase the chance of you getting a new infection – for example tuberculosis (TB), shingles or viral hepatitis.

Tell your doctor straight away if you notice signs of infection, such as:

- Fever, sweating, chills, weight loss, or a cough that won't go away – these may be signs of TB.
- Painful skin rash with blisters – this may be a sign of shingles.
- Feeling tired or short of breath – this may be a sign of pneumonia.

Vaccines – used to help prevent infections

Live vaccines (for example influenza vaccine by nasal spray, varicella, measles/mumps/rubella) should not be given during RINVOQ® treatment, or just before starting RINVOQ® treatment.
Before being given any vaccines, talk to your doctor – they will know which vaccines you should **not** be given before or during treatment with RINVOQ®.

Cholesterol

Your doctor will check your cholesterol levels while you are taking RINVOQ® – this is to decide if you need to start a medicine to lower your cholesterol levels.

Contraception, pregnancy, and breast-feeding

RINVOQ® must not be taken during pregnancy.

- Use effective contraception while taking RINVOQ® – and for 4 weeks after your last dose. Talk to your doctor about effective contraception.
- Tell your doctor straight away if you wish to become pregnant, or if you become pregnant.
- Do not breast-feed while using RINVOQ®.

Blood clots in veins (DVT) or lungs (PE)

Tell your doctor straight away if you get signs of DVT or PE, such as a painful swollen leg or chest pain.